{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T22:27:22Z","timestamp":1750112842460},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin J Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s40880-015-0032-8","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T10:31:32Z","timestamp":1438943492000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement"],"prefix":"10.1186","volume":"34","author":[{"given":"Sha","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma-Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zu-Lu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,8]]},"reference":[{"key":"32_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00432-007-0320-z","volume":"134","author":"H Sasaki","year":"2008","unstructured":"Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol. 2008;134:569\u201377.","journal-title":"J Cancer Res Clin Oncol"},{"key":"32_CR2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"32_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472\u201380.","journal-title":"N Engl J Med"},{"key":"32_CR4","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","volume":"24","author":"A Inoue","year":"2006","unstructured":"Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340\u20136.","journal-title":"J Clin Oncol"},{"key":"32_CR5","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","volume":"131","author":"K Rikova","year":"2007","unstructured":"Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190\u2013203.","journal-title":"Cell"},{"key":"32_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561\u20136.","journal-title":"Nature"},{"key":"32_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","volume":"46","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46:1773\u201380.","journal-title":"Eur J Cancer"},{"key":"32_CR8","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","volume":"15","author":"K Takeuchi","year":"2009","unstructured":"Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15:3143\u20139.","journal-title":"Clin Cancer Res"},{"key":"32_CR9","doi-asserted-by":"publisher","first-page":"e31323","DOI":"10.1371\/journal.pone.0031323","volume":"7","author":"Y Togashi","year":"2012","unstructured":"Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012;7:e31323.","journal-title":"PLoS One"},{"key":"32_CR10","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-08-1018","volume":"14","author":"K Takeuchi","year":"2008","unstructured":"Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14:6618\u201324.","journal-title":"Clin Cancer Res"},{"key":"32_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/BJ20090387","volume":"420","author":"RH Palmer","year":"2009","unstructured":"Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420:345\u201361.","journal-title":"Biochem J"},{"key":"32_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.24181","volume":"115","author":"DW Wong","year":"2009","unstructured":"Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723\u201333.","journal-title":"Cancer"},{"key":"32_CR13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693\u2013703.","journal-title":"N Engl J Med"},{"key":"32_CR14","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385\u201394.","journal-title":"N Engl J Med"},{"key":"32_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011\u20139.","journal-title":"Lancet Oncol"},{"key":"32_CR16","doi-asserted-by":"publisher","first-page":"e114008","DOI":"10.1371\/journal.pone.0114008","volume":"9","author":"YB Cao","year":"2014","unstructured":"Cao YB, Xiao GL, Qiu XB, Ye S, Lin TY. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. PLoS One. 2014;9:e114008.","journal-title":"PLoS One"},{"key":"32_CR17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/PAS.0b013e3182233e06","volume":"35","author":"A Yoshida","year":"2011","unstructured":"Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35:1226\u201334.","journal-title":"Am J Surg Pathol"},{"key":"32_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","volume":"3","author":"K Inamura","year":"2008","unstructured":"Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13\u20137.","journal-title":"J Thorac Oncol"},{"key":"32_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1245\/s10434-009-0808-7","volume":"17","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889\u201397.","journal-title":"Ann Surg Oncol"},{"key":"32_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/JTO.0b013e31819e7814","volume":"4","author":"P Goldstraw","year":"2009","unstructured":"Goldstraw P. The 7th edition of TNM in lung cancer: what now? J Thorac Oncol. 2009;4:671\u20133.","journal-title":"J Thorac Oncol"},{"key":"32_CR21","unstructured":"Travis W, Brambilla E, Muller-Hermelink H, Harris CC. Pathology and genetics of yumours of the lung, pleura, thymus and heart. 3rd ed. Lyon, France: IARC Press. World Health Organization Classification of Tumours; 2004; vol 10."},{"key":"32_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1158\/1078-0432.CCR-10-0208","volume":"17","author":"YH Li","year":"2011","unstructured":"Li YH, Wang F, Shen L, Deng YM, Shao QO, Feng F, et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clin Cancer Res. 2011;17:382\u201390.","journal-title":"Clin Cancer Res"},{"key":"32_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/his.12037","volume":"62","author":"E Conde","year":"2013","unstructured":"Conde E, Angulo B, Izquierdo E, Munoz L, Suarez-Gauthier A, Plaza C, et al. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Histopathology. 2013;62:609\u201316.","journal-title":"Histopathology"},{"key":"32_CR24","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","volume":"15","author":"SJ Rodig","year":"2009","unstructured":"Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15:5216\u201323.","journal-title":"Clin Cancer Res"},{"key":"32_CR25","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","volume":"16","author":"DR Camidge","year":"2010","unstructured":"Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010;16:5581\u201390.","journal-title":"Clin Cancer Res"},{"key":"32_CR26","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2353\/ajpath.2009.080755","volume":"174","author":"MP Martelli","year":"2009","unstructured":"Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174:661\u201370.","journal-title":"Am J Pathol"},{"key":"32_CR27","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247\u201353.","journal-title":"J Clin Oncol"},{"key":"32_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.5858\/arpa.2011-0321-OA","volume":"136","author":"ML Wallander","year":"2012","unstructured":"Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma implications for optimal clinical testing. Arch Pathol Lab Med. 2012;136:796\u2013803.","journal-title":"Arch Pathol Lab Med"},{"key":"32_CR29","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/annonc\/mdr489","volume":"22","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616\u201324.","journal-title":"Ann Oncol"},{"key":"32_CR30","doi-asserted-by":"publisher","first-page":"e69016","DOI":"10.1371\/journal.pone.0069016","volume":"8","author":"Y Li","year":"2013","unstructured":"Li Y, Pan YJ, Wang R, Sun YH, Hu HC, Shen XX, et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One. 2013;8:e69016.","journal-title":"PLoS One"},{"key":"32_CR31","doi-asserted-by":"publisher","first-page":"19893","DOI":"10.1073\/pnas.0805381105","volume":"105","author":"M Soda","year":"2008","unstructured":"Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA. 2008;105:19893\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"32_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/modpathol.2009.2","volume":"22","author":"K Inamura","year":"2009","unstructured":"Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22:508\u201315.","journal-title":"Mod Pathol"},{"key":"32_CR33","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","volume":"14","author":"JP Koivunen","year":"2008","unstructured":"Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275\u201383.","journal-title":"Clin Cancer Res"},{"key":"32_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/1476-4598-9-188","volume":"9","author":"X Zhang","year":"2010","unstructured":"Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188.","journal-title":"Mol Cancer"},{"key":"32_CR35","doi-asserted-by":"publisher","first-page":"e101551","DOI":"10.1371\/journal.pone.0101551","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Cai Y, Dong Y, Nong J, Zhou L, Liu G, et al. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR. PLoS One. 2014;9:e101551.","journal-title":"PLoS One"},{"key":"32_CR36","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1097\/JTO.0b013e3181f43274","volume":"5","author":"YW Kuo","year":"2010","unstructured":"Kuo YW, Wu SG, Ho CC, Shih JY. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol. 2010;5:2039\u201340.","journal-title":"J Thorac Oncol"},{"key":"32_CR37","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1097\/JTO.0b013e31822eec5e","volume":"6","author":"S Popat","year":"2011","unstructured":"Popat S, Vieira de Araujo A, Min T, Swansbury J, Dainton M, Wotherspoon A, et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol. 2011;6:1962\u20133.","journal-title":"J Thorac Oncol"},{"key":"32_CR38","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","volume":"71","author":"T Sasaki","year":"2011","unstructured":"Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71:6051\u201360.","journal-title":"Cancer Res"},{"key":"32_CR39","doi-asserted-by":"publisher","first-page":"e107276","DOI":"10.1371\/journal.pone.0107276","volume":"9","author":"C Li","year":"2014","unstructured":"Li C, Hao L, Li Y, Wang S, Chen H, Zhang L, et al. Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer. PLoS One. 2014;9:e107276.","journal-title":"PLoS One"},{"key":"32_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5732\/cjc.012.10160","volume":"32","author":"H Suzuki","year":"2013","unstructured":"Suzuki H, Hirashima T, Okmoto N, Yamadori T, Tamiya M, Morishita N, et al. The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations. Chin J Cancer. 2013;32:136\u201340.","journal-title":"Chin J Cancer"},{"key":"32_CR41","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.1747-0285.2011.01239.x","volume":"78","author":"S Zhang","year":"2011","unstructured":"Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011;78:999\u20131005.","journal-title":"Chem Biol Drug Des"},{"key":"32_CR42","first-page":"190","volume":"4","author":"JN Spaans","year":"2014","unstructured":"Spaans JN, Goss GD. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Front Oncol. 2014;4:190.","journal-title":"Front Oncol"}],"container-title":["Chinese Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-015-0032-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-015-0032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T20:54:12Z","timestamp":1526158452000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancercommun.biomedcentral.com\/articles\/10.1186\/s40880-015-0032-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,8]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1186\/s40880-015-0032-8","relation":{},"ISSN":["1944-446X"],"issn-type":[{"value":"1944-446X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,8]]},"article-number":"35"}}